Естонија - Естонски - Ravimiamet

stada arzneimittel ag - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 56tk

Естонија - Естонски - Ravimiamet

stada arzneimittel ag - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 14tk; 240mg 180tk; 240mg 28tk

Естонија - Естонски - Ravimiamet

norameda uab - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 14tk

Естонија - Естонски - Ravimiamet

norameda uab - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 56tk

Естонија - Естонски - Ravimiamet

teva gmbh - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 100tk; 120mg 14tk

Естонија - Естонски - Ravimiamet

teva gmbh - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 168tk

Естонија - Естонски - Ravimiamet

gedeon richter plc. - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 14tk

Естонија - Естонски - Ravimiamet

gedeon richter plc. - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 168tk

Европска Унија - Естонски - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubitsiini vesinikkloriid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastilised ained - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).